GtoPdb Ligand ID: 8997

Synonyms: CL-2C | NVP-QGE031 | QGE031
Compound class: Antibody
Comment: Ligelizumab is a humanized, investigational high-affinity anti-IgE monoclonal antibody with anti-inflammatory potential [1], with improved pharmacokinetics and clinical effects compared to omalizumab.
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide sequence analysis reveals identical matches with antibody sequences claimed in patent US7531169 B2, where it is the clone designated as CL-2C [3].
No information available.
Summary of Clinical Use
Several Phase II clinical trials are underway to evaluate the potential of QGE031 as a treatment for asthma and chronic spontaneous urticaria [2].
Mechanism Of Action and Pharmacodynamic Effects
IgE acts as an environmental sensor facilitating an immune response via the high-affinity IgE receptor, FcεRI. This action sensitizes mast cells to specific antigens which, upon allergen exposure, release pro-inflammatory cytokines and other mediators of the allergic response. Ligelizumab is designed to bind to circulating IgE, thereby reducing IgE-mediated responses.